May 07, 2020
Syndax Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Clinical and Business Update
May 06, 2020
Theravance Biopharma, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
Apr 28, 2020
Theravance Biopharma to Report First Quarter 2020 Financial Results on May 6, 2020
Apr 23, 2020
Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19
Apr 13, 2020
Ascletis Receives IND Approval for its HIV Drug ASC09F
Mar 24, 2020
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients
Mar 06, 2020
European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis
Feb 24, 2020
Theravance Biopharma, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
Feb 18, 2020
Theravance Biopharma Announces Presentations at Upcoming Investor Conferences
Jan 31, 2020
AbbVie Receives Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks in Genotype 3, Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis
Jan 07, 2020
Theravance Biopharma Announces Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Dec 03, 2019
Theravance Biopharma Announces Dosing of First Patient in Phase 2 Allergen Challenge Study of TD-8236, an Investigational, Lung-Selective, Inhaled Pan-Janus Kinase (JAK) Inhibitor for Inflammatory Lung Diseases
Nov 07, 2019
Syndax Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Clinical and Business Update
Nov 06, 2019
Theravance Biopharma to Present at the 2019 Credit Suisse Healthcare Conference
Oct 29, 2019
Theravance Biopharma to Report Third Quarter 2019 Financial Results on November 5
Oct 21, 2019
Theravance Biopharma and Mylan to Present New Data on YUPELRI® (revefenacin) at the 2019 CHEST Annual Meeting
Sep 26, 2019
AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes
Sep 25, 2019
Theravance Biopharma to Present at the 2019 Cantor Global Healthcare Conference
Aug 28, 2019
Theravance Biopharma to Present at Two Upcoming Investor Conferences
Jul 31, 2019
Theravance Biopharma, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update